Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Barchart · 2d ago

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.